Promising approaches in cancer immunotherapy
Immunotherapy is a promising field, which enhances and harnesses the powers of the host immune system against cancer and in recent years, has become a major application of the fundamental research of cancer immunology. Cancer immunotherapy is often more targeted than non-specific therapy approaches,...
Gespeichert in:
Veröffentlicht in: | Immunobiology (1979) 2020-03, Vol.225 (2), p.151875-151875, Article 151875 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 151875 |
---|---|
container_issue | 2 |
container_start_page | 151875 |
container_title | Immunobiology (1979) |
container_volume | 225 |
creator | Taefehshokr, Nima Baradaran, Behzad Baghbanzadeh, Amir Taefehshokr, Sina |
description | Immunotherapy is a promising field, which enhances and harnesses the powers of the host immune system against cancer and in recent years, has become a major application of the fundamental research of cancer immunology. Cancer immunotherapy is often more targeted than non-specific therapy approaches, including radiotherapy or chemotherapy, as the immune system can be trained to remember cancer cells, highlighting a durable approach that can be maintained after the treatment completion. Immunotherapy functions by directing the immune system to attack the tumour cells via targeting tumour antigens, also enhancing the existing anti-tumour immune responses. Current strategies include non-specific immunotherapy, cancer vaccines, oncolytic virus therapy, monoclonal antibodies, immune checkpoints and T cell therapy. The combination of effective approaches can increase the immunotherapy efficacy, leading to durable anti-tumour immune responses. This review will discuss the immunotherapy approaches, particularly immune checkpoints and T cell therapy, which are the most common clinical applications in cancer immunotherapy. |
doi_str_mv | 10.1016/j.imbio.2019.11.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2322804085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0171298519302517</els_id><sourcerecordid>2322804085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-37f07bd0199f89a639c12d9087c822a6bf5ca784c3ba66fe1d039c6a54c53ee83</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwC5BQRgYSfHYSOwMDqviSKsEAs-U4F-qq-cBOKvXf49LCyHTLc_e-9xByCTQBCvntKrFNabuEUSgSgIQCPSJTkELGnInimEwpCIhZIbMJOfN-RQPIhDwlEw4SGE_5lNy8ua6x3rafke5712mzRB_ZNjK6Negi2zRj2w1LdLrfnpOTWq89XhzmjHw8PrzPn-PF69PL_H4Rm5RlQ8xFTUVZhbSiloXOeWGAVQWVwkjGdF7WmdFCpoaXOs9rhIoGJNdZajKOKPmMXO_vhkJfI_pBhYoG12vdYjd6xThjkqZUZgHle9S4znuHteqdbbTbKqBqp0mt1I8mtdOkAFTQFLauDgFj2WD1t_PrJQB3ewDDmxuLTnljMRiprEMzqKqz_wZ8A-3uePg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322804085</pqid></control><display><type>article</type><title>Promising approaches in cancer immunotherapy</title><source>Access via ScienceDirect (Elsevier)</source><creator>Taefehshokr, Nima ; Baradaran, Behzad ; Baghbanzadeh, Amir ; Taefehshokr, Sina</creator><creatorcontrib>Taefehshokr, Nima ; Baradaran, Behzad ; Baghbanzadeh, Amir ; Taefehshokr, Sina</creatorcontrib><description>Immunotherapy is a promising field, which enhances and harnesses the powers of the host immune system against cancer and in recent years, has become a major application of the fundamental research of cancer immunology. Cancer immunotherapy is often more targeted than non-specific therapy approaches, including radiotherapy or chemotherapy, as the immune system can be trained to remember cancer cells, highlighting a durable approach that can be maintained after the treatment completion. Immunotherapy functions by directing the immune system to attack the tumour cells via targeting tumour antigens, also enhancing the existing anti-tumour immune responses. Current strategies include non-specific immunotherapy, cancer vaccines, oncolytic virus therapy, monoclonal antibodies, immune checkpoints and T cell therapy. The combination of effective approaches can increase the immunotherapy efficacy, leading to durable anti-tumour immune responses. This review will discuss the immunotherapy approaches, particularly immune checkpoints and T cell therapy, which are the most common clinical applications in cancer immunotherapy.</description><identifier>ISSN: 0171-2985</identifier><identifier>EISSN: 1878-3279</identifier><identifier>DOI: 10.1016/j.imbio.2019.11.010</identifier><identifier>PMID: 31812343</identifier><language>eng</language><publisher>Netherlands: Elsevier GmbH</publisher><subject>Cancer immunotherapy ; Immune checkpoint ; T cell therapy</subject><ispartof>Immunobiology (1979), 2020-03, Vol.225 (2), p.151875-151875, Article 151875</ispartof><rights>2019 Elsevier GmbH</rights><rights>Copyright © 2019 Elsevier GmbH. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-37f07bd0199f89a639c12d9087c822a6bf5ca784c3ba66fe1d039c6a54c53ee83</citedby><cites>FETCH-LOGICAL-c425t-37f07bd0199f89a639c12d9087c822a6bf5ca784c3ba66fe1d039c6a54c53ee83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.imbio.2019.11.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31812343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taefehshokr, Nima</creatorcontrib><creatorcontrib>Baradaran, Behzad</creatorcontrib><creatorcontrib>Baghbanzadeh, Amir</creatorcontrib><creatorcontrib>Taefehshokr, Sina</creatorcontrib><title>Promising approaches in cancer immunotherapy</title><title>Immunobiology (1979)</title><addtitle>Immunobiology</addtitle><description>Immunotherapy is a promising field, which enhances and harnesses the powers of the host immune system against cancer and in recent years, has become a major application of the fundamental research of cancer immunology. Cancer immunotherapy is often more targeted than non-specific therapy approaches, including radiotherapy or chemotherapy, as the immune system can be trained to remember cancer cells, highlighting a durable approach that can be maintained after the treatment completion. Immunotherapy functions by directing the immune system to attack the tumour cells via targeting tumour antigens, also enhancing the existing anti-tumour immune responses. Current strategies include non-specific immunotherapy, cancer vaccines, oncolytic virus therapy, monoclonal antibodies, immune checkpoints and T cell therapy. The combination of effective approaches can increase the immunotherapy efficacy, leading to durable anti-tumour immune responses. This review will discuss the immunotherapy approaches, particularly immune checkpoints and T cell therapy, which are the most common clinical applications in cancer immunotherapy.</description><subject>Cancer immunotherapy</subject><subject>Immune checkpoint</subject><subject>T cell therapy</subject><issn>0171-2985</issn><issn>1878-3279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EoqXwC5BQRgYSfHYSOwMDqviSKsEAs-U4F-qq-cBOKvXf49LCyHTLc_e-9xByCTQBCvntKrFNabuEUSgSgIQCPSJTkELGnInimEwpCIhZIbMJOfN-RQPIhDwlEw4SGE_5lNy8ua6x3rafke5712mzRB_ZNjK6Negi2zRj2w1LdLrfnpOTWq89XhzmjHw8PrzPn-PF69PL_H4Rm5RlQ8xFTUVZhbSiloXOeWGAVQWVwkjGdF7WmdFCpoaXOs9rhIoGJNdZajKOKPmMXO_vhkJfI_pBhYoG12vdYjd6xThjkqZUZgHle9S4znuHteqdbbTbKqBqp0mt1I8mtdOkAFTQFLauDgFj2WD1t_PrJQB3ewDDmxuLTnljMRiprEMzqKqz_wZ8A-3uePg</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Taefehshokr, Nima</creator><creator>Baradaran, Behzad</creator><creator>Baghbanzadeh, Amir</creator><creator>Taefehshokr, Sina</creator><general>Elsevier GmbH</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202003</creationdate><title>Promising approaches in cancer immunotherapy</title><author>Taefehshokr, Nima ; Baradaran, Behzad ; Baghbanzadeh, Amir ; Taefehshokr, Sina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-37f07bd0199f89a639c12d9087c822a6bf5ca784c3ba66fe1d039c6a54c53ee83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer immunotherapy</topic><topic>Immune checkpoint</topic><topic>T cell therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taefehshokr, Nima</creatorcontrib><creatorcontrib>Baradaran, Behzad</creatorcontrib><creatorcontrib>Baghbanzadeh, Amir</creatorcontrib><creatorcontrib>Taefehshokr, Sina</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunobiology (1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taefehshokr, Nima</au><au>Baradaran, Behzad</au><au>Baghbanzadeh, Amir</au><au>Taefehshokr, Sina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Promising approaches in cancer immunotherapy</atitle><jtitle>Immunobiology (1979)</jtitle><addtitle>Immunobiology</addtitle><date>2020-03</date><risdate>2020</risdate><volume>225</volume><issue>2</issue><spage>151875</spage><epage>151875</epage><pages>151875-151875</pages><artnum>151875</artnum><issn>0171-2985</issn><eissn>1878-3279</eissn><abstract>Immunotherapy is a promising field, which enhances and harnesses the powers of the host immune system against cancer and in recent years, has become a major application of the fundamental research of cancer immunology. Cancer immunotherapy is often more targeted than non-specific therapy approaches, including radiotherapy or chemotherapy, as the immune system can be trained to remember cancer cells, highlighting a durable approach that can be maintained after the treatment completion. Immunotherapy functions by directing the immune system to attack the tumour cells via targeting tumour antigens, also enhancing the existing anti-tumour immune responses. Current strategies include non-specific immunotherapy, cancer vaccines, oncolytic virus therapy, monoclonal antibodies, immune checkpoints and T cell therapy. The combination of effective approaches can increase the immunotherapy efficacy, leading to durable anti-tumour immune responses. This review will discuss the immunotherapy approaches, particularly immune checkpoints and T cell therapy, which are the most common clinical applications in cancer immunotherapy.</abstract><cop>Netherlands</cop><pub>Elsevier GmbH</pub><pmid>31812343</pmid><doi>10.1016/j.imbio.2019.11.010</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-2985 |
ispartof | Immunobiology (1979), 2020-03, Vol.225 (2), p.151875-151875, Article 151875 |
issn | 0171-2985 1878-3279 |
language | eng |
recordid | cdi_proquest_miscellaneous_2322804085 |
source | Access via ScienceDirect (Elsevier) |
subjects | Cancer immunotherapy Immune checkpoint T cell therapy |
title | Promising approaches in cancer immunotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A17%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Promising%20approaches%20in%20cancer%20immunotherapy&rft.jtitle=Immunobiology%20(1979)&rft.au=Taefehshokr,%20Nima&rft.date=2020-03&rft.volume=225&rft.issue=2&rft.spage=151875&rft.epage=151875&rft.pages=151875-151875&rft.artnum=151875&rft.issn=0171-2985&rft.eissn=1878-3279&rft_id=info:doi/10.1016/j.imbio.2019.11.010&rft_dat=%3Cproquest_cross%3E2322804085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322804085&rft_id=info:pmid/31812343&rft_els_id=S0171298519302517&rfr_iscdi=true |